CompletedNCT01625897
Long-Term MP-214 Study in Chronic or Older Adults With Schizophrenia
About this title
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Read the official source — NCT01625897Medication studyAges 20–74Japan
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 74 years. Other eligibility criteria applied.
- Listed locations
- Aizu-WakamatsuSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateMay 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 125
- Sponsor
- Tanabe Pharma Corporation
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Japan
- Age range
- From 20 Years to 74 Years
- Official registry ID
- NCT01625897
- Official title
Show the full official title
A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Get this study by email
Recruitment & locations
CompletedAizu-Wakamatsu
Questions about this study
Who is behind this study?
The study sponsor is Tanabe Pharma Corporation, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including MP-214 and Risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 74 years. Other eligibility criteria applied.
